903 related articles for article (PubMed ID: 21888837)
1. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
[TBL] [Abstract][Full Text] [Related]
3. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK.
Karnon J; Brennan A; Pandor A; Fowkes G; Lee A; Gray D; Coshall C; Nicholls C; Akehurst R
Curr Med Res Opin; 2005 Jan; 21(1):101-12. PubMed ID: 15881481
[TBL] [Abstract][Full Text] [Related]
4. Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention.
Chaturvedi S
Clin Ther; 2008 Jul; 30(7):1196-205. PubMed ID: 18691981
[TBL] [Abstract][Full Text] [Related]
5. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Diener HC; Sacco R; Yusuf S; ;
Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
[TBL] [Abstract][Full Text] [Related]
6. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Sep; 10(5):331-42. PubMed ID: 22853743
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
Matchar DB; Samsa GP; Liu S
Value Health; 2005; 8(5):572-80. PubMed ID: 16176495
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
Main C; Palmer S; Griffin S; Jones L; Orton V; Sculpher M; Henderson R; Sudlow C; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(40):iii-iv, xv-xvi, 1-141. PubMed ID: 15461878
[TBL] [Abstract][Full Text] [Related]
9. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
De Schryver EL; Algra A; van Gijn J
Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
[TBL] [Abstract][Full Text] [Related]
10. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
Shah H; Gondek K
Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
[TBL] [Abstract][Full Text] [Related]
11. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.
Rogowski W; Burch J; Palmer S; Craigs C; Golder S; Woolacott N
Health Technol Assess; 2009 Jun; 13(31):iii-iv, ix-xi, 1-77. PubMed ID: 19573471
[TBL] [Abstract][Full Text] [Related]
12. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
13. [Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].
Haldemann R; Lüscher TF; Szucs TD
Praxis (Bern 1994); 2001 Mar; 90(13):539-45. PubMed ID: 11550619
[TBL] [Abstract][Full Text] [Related]
14. [The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review].
Schellinger PD; Jüttler E; Meyding-Lamadé UK; Schwark C
Fortschr Neurol Psychiatr; 2004 May; 72(5):270-81. PubMed ID: 15136948
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke.
Ringleb PA; Schwark C; Schwaninger M; Schellinger PD
Expert Opin Pharmacother; 2005 Mar; 6(3):359-67. PubMed ID: 15794727
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
Aronow WS
Drugs Aging; 1999 Aug; 15(2):91-101. PubMed ID: 10495069
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
Schleinitz MD; Weiss JP; Owens DK
Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
[TBL] [Abstract][Full Text] [Related]
18. Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pouwels XGLV; Wolff R; Ramaekers BLT; Van Giessen A; Lang S; Ryder S; Worthy G; Duffy S; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 May; 36(5):533-543. PubMed ID: 29344794
[TBL] [Abstract][Full Text] [Related]
19. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.
Greenhalgh J; Bagust A; Boland A; Saborido CM; Fleeman N; McLeod C; Dundar Y; Dickson R; Proudlove C; Kolamunnage-Dona R; Fisher M
Health Technol Assess; 2010 May; 14 Suppl 1():31-8. PubMed ID: 20507801
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
Chambers M; Hutton J; Gladman J
Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
